BAYRY BAYER AG S/ADR Загрузка... : Бычьи и медвежьи мнения аналитиков

Загрузка графика...
Лучшие сигналы
Лента
Загрузка...
Загрузка...
Загрузка...
Загрузка...
Загрузка...
Загрузка...
Весь контент
Ленты источников
Buzzberg Топ 50
Все капитализацииБез фильтра по капитализации
200 млрд и вышеМега
от 10 до 200 млрдКрупные
от 2 до 10 млрдСредние
от 0 до 2 млрдМалые
Свой
Введите диапазон капитализации в млрд USD
Все направления
▲ Лонг
▼ Шорт
⛔ Избегать
✂ Закрытие
◦ Другие
Любая оценка
Низкая+
Средняя+
Высокая
? ?
08:36
02 июл
Bloomberg Newswire (@business)
Bayer is placing its US glyphosate business into a newly formed entity called Ruveon according.
Bayer is placing its US glyphosate business into a newly formed entity called Ruveon according to the report.
18:40
25 июн
Bloomberg Newswire (@business)
Bayer secures a major legal victory in the Supreme Court over Roundup weedkiller lawsuits after.
Bayer secures a major legal victory in the Supreme Court over Roundup weedkiller lawsuits after years of costly setbacks.
14:01
25 июн
zerohedge Финансовый блог / агрегатор новостей
Supreme Court ruling shields Bayer from Roundup cancer-warning lawsuits.
Supreme Court ruling shields Bayer from Roundup cancer-warning lawsuits, removing a major legal liability.
17:40
23 июн
FirstSquawk Newswire (@FirstSquawk)
Eli Lilly and Bayer criticize Germany's spending on innovative medicines.
Eli Lilly and Bayer criticize Germany's spending on innovative medicines, warning current policies could undermine pharmaceutical investment attractiveness, as reported by the Financial Times.
05:44
12 июн
Bloomberg Newswire (@business)
Bayer shares face a make-or-break few weeks with two upcoming court developments key.
Bayer shares face a make-or-break few weeks with two upcoming court developments key to stemming a wipeout in market value.
08:30
01 июн
Reuters Business Newswire (@ReutersBiz)
Bayer's Monsanto debacle is analyzed in a Breakingviews column highlighting bitter M&A lessons.
Bayer's Monsanto debacle is analyzed in a Breakingviews column highlighting bitter M&A lessons from the acquisition.
06:15
01 июн
Reuters Business Newswire (@ReutersBiz)
Bayer's Monsanto debacle is analyzed in a Breakingviews column highlighting bitter M&A lessons.
Bayer's Monsanto debacle is analyzed in a Breakingviews column highlighting bitter M&A lessons from the acquisition.
13:00
06 мая
Chuck Magro CEO, Corteva, Inc. CTVA Q1 FY26 call
The Bayer licensing agreement is driving stronger-than-expected demand for Corteva's seed technology, positioning the company to become royalty positive ahead of schedule.
BAYRY
Выс.
17:14
04 мар
Bayer said a US judge granted preliminary approval for its $7.25 billion settlement proposal.
Bayer said a US judge granted preliminary approval for its $7.25 billion settlement proposal aimed at containing its liability from thousands of lawsuits over Roundup weedkiller, which have weighed on the German company for years. https://t.co/3PGGrHg0vV
16:36
26 фев
Positive Phase 3 trial data for a key drug combination is a significant fundamental catalyst.
Positive Phase 3 trial data for a key drug combination is a significant fundamental catalyst that should drive the stock price higher.
BAYRY
Сред.
21:43
18 фев
Bayer faces significant headwinds as its Roundup settlement is met with skepticism.
Bayer faces significant headwinds as its Roundup settlement is met with skepticism, coupled with a direct company warning of negative cash flow and ongoing litigation risk.
BAYRY
Сред.
14:00
04 фев
Chuck Magro CEO, Corteva, Inc. CTVA Q4 FY25 call
Bayer settlement accelerates Corteva's corn licensing to 2027 (5 years early) and introduces cotton licensing, with a $1B EBITDA upside over 10 years. — Opens new revenue streams for Corteva and potentially increases competitive pressure on Bayer's seed businesses.
BAYRY
Выс.
13:30
30 янв
Chris Fethmore CFO, Regeneron Pharmaceuticals, Inc. REGN Q4 FY25 call
Bayer collaboration on Eylea products remains a substantial source of international revenue and profit.
BAYRY
Выс.
08:30
29 янв
Thermo Fisher's Oncomind DX test was FDA-approved as a companion diagnostic for Bayer's therapy, strengthening Bayer's targeted lung cancer treatment and driving demand for Thermo Fisher's NGS diagnostics.
BAYRY
Выс.

Об аналитическом покрытии BAYRY

Buzzberg отслеживает BAYRY (BAYER AG S/ADR) в 5 источниках. Бычьих сигналов: 0, медвежьих: 0, от 9 аналитиков. Сентимент разделён поровну. Всего отслеживается 14 торговых идей. Последние спикеры: Bloomberg, zerohedge, FirstSquawk.